FDA Approves Rasonque for Pancreatic Cancer
The Spin
Narrative A
This is a critical breakthrough for one of medicine's most brutal diseases. Daraxonrasib nearly doubled median survival in patients who had already failed chemotherapy, and some lived for years. For a cancer with a five-year survival rate of just 13%, that kind of result is extraordinary.
Narrative B
Rasonque's approval matters beyond just pancreatic cancer — KRAS inhibition cracks open a target that defined "undruggable" for four decades, affecting roughly 20% of all cancers worldwide. First-line combination studies are already posting response rates near 60%, and the same mechanism could eventually reach colorectal, lung and even rare childhood cancers. This is the beginning of an entirely new class of treatments.
Establishment-critical narrative
Today's FDA approval is a major new option, but not a cure. Rasonque nearly doubled median survival in previously treated metastatic pancreatic cancer, however, patients still progressed, and resistance emerged in 59% of those studied for its mechanisms. The next combinations remain largely preclinical, so the real test is whether this survival gain can become durable.